|Day Low/High||2.97 / 3.10|
|52 Wk Low/High||1.85 / 4.09|
Cash runway updated into October 2018
Recent Pre-NDA Meeting Provided Guidance on Female Only NDA Filing Strategy and Post-Approval Safety Study
Call Scheduled for October 31st at 9am ET
505(b)(2) NDA on track for FDA submission in Q1 2018
Data expected in Q4 2017 followed by a 505(b)(2) NDA submission in late 2017/early 2018
Expected to be final clinical trial prior to 505(b)(2) NDA submission
Company on track for late 2017/early 2018 submission
Data Demonstrate Gimoti Significantly Improves Symptoms in Women with Moderate to Severe Diabetic Gastroparesis
Company reaffirms NDA submission by year end 2017
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.